首页> 外文OA文献 >POS1052 PSORIATIC ARTHRITIS AND OBESITY IMPACT DRUG PERSISTENCE IN USTEKINUMAB-TREATED PATIENTS WITH PSORIASIS IN THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGIC AND IMMUNOMODULATORS REGISTER (BADBIR): A 10-YEAR FOLLOW-UP STUDY

【2h】

POS1052 PSORIATIC ARTHRITIS AND OBESITY IMPACT DRUG PERSISTENCE IN USTEKINUMAB-TREATED PATIENTS WITH PSORIASIS IN THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGIC AND IMMUNOMODULATORS REGISTER (BADBIR): A 10-YEAR FOLLOW-UP STUDY

机译：POS1052银屑病关节炎和肥胖症在英国皮肤科医生中牛皮癣患者的牛皮癣患者（Badbir）：10年的后续研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
A. Ogdie; W. Tillett; A. Passey; P. Gorecki;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) [J] . Yiu Z. Z. N., Mason K. J., Hampton P. J., British Journal of Dermatology . 2020,第2期

机译：牛皮癣患者Adalimalab，Ustekuinub和Secukinumab的药物存活：英国皮肤科生物制剂和免疫调节器注册的前瞻性队列研究（Badbir）
2. Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR BADBIR ) [J] . Mahil S.K., Wilson N., Dand N., British Journal of Dermatology . 2020,第5期

机译：牛皮癣治疗目标：使用来自现实世界的群组的数据（英国皮肤病学家生物制剂和免疫调节器，Badbir Badbir，使用来自基于人口的群组的数据（英国皮肤科学家协会）定义牛皮癣的结果
3. Differential Drug Survival of Second-line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) [J] . Iskandar Ireny Y. K., Warren Richard B., Lunt Mark, The Journal of investigative dermatology. . 2018,第4期

机译：牛皮癣患者二线生物疗法的差异药物存活：英国皮肤病学生物干预率注册的英国医学群体研究（BADBIR）
4. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) [O] . Ireny Y.K. Iskandar, Richard B. Warren, Mark Lunt, -1

机译：银屑病患者二线生物疗法的差异药物存活率：英国皮肤科医生生物干预协会（BADBIR）的观察性队列研究
5. Differential Drug Survival of Second-Line Biologic Therapies In Patients with Psoriasis:Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) [O] . Iskandar, Ireny Y K, Warren, Richard B, Lunt, Mark, 2017

机译：银屑病患者二线生物治疗的差异药物存活：来自英国皮肤病学家协会生物干预登记处（BaDBIR）的观察性队列研究

POS1052 PSORIATIC ARTHRITIS AND OBESITY IMPACT DRUG PERSISTENCE IN USTEKINUMAB-TREATED PATIENTS WITH PSORIASIS IN THE BRITISH ASSOCIATION OF DERMATOLOGISTS BIOLOGIC AND IMMUNOMODULATORS REGISTER (BADBIR): A 10-YEAR FOLLOW-UP STUDY

著录项

相似文献

相关主题

期刊订阅